BEONEBIO
DEAD

Serial Number

98746793

Owner

BeiGene Switzerland GMBH

Attorney

Kristen Ruisi

Filing Date

Sep 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BEONEBIO Trademark

Serial Number: 98746793

BEONEBIO is a trademark filed by BeiGene Switzerland GMBH on September 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

BeiGene Switzerland GMBH

Aeschengraben 27
Basel 4051 , CH

Entity Type: 16

Trademark Details

Filing Date

September 12, 2024

Registration Date

Not Registered

Published for Opposition

September 9, 2025

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice

Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design

Filing History

ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Apr 9, 2026 MAB5
ABANDONMENT - AFTER PUBLICATION
Apr 9, 2026 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Apr 8, 2026 EXAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 4, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 9, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 9, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 3, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 8, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 22, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 22, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 22, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 22, 2025 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 17, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 17, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 17, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 12, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 24, 2025 NWOS
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Sep 16, 2024 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Sep 16, 2024 PARI
NEW APPLICATION ENTERED
Sep 12, 2024 NWAP